NGL Fine-Chem Ltd. · NSE:NGLFINE

NGL Fine-Chem — Q4 FY2021 Earnings Presentation

19 slides from NGL Fine-Chem's earnings presentation, Jul 30, 2021

  1. Slide 1: Earnings Presentation Q4 & FY21

    Earnings Presentation Q4 & FY21

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by NGL Fine-Chem Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti

  3. Slide 3: Q4 & FY21 Financial Highlights

    Q4 & FY21 Financial Highlights

  4. Slide 4: Strong Q4FY21 and FY21 performance

    Strong Q4FY21 and FY21 performance Consolidated Figures Q4FY21 FY21 Revenue from operations 102% Revenue from operations 70% Rs 72 crores Rs 258 crores EBITDA 807% EBITDA 311% Rs 21 crores Rs 80 crores EBITDA Margins: 29.0% EBITDA Margins: 30.9% Profit after tax Q4FY20: Rs -0.2 crores Profit after t

  5. Slide 5: Growth across segments driven by increasing market share

    Growth across segments driven by increasing market share FY21 Revenue Distribution Revenue (Rs Cr) FY21 FY20 YoY % Human API, 8% Intermediates, 7% Veterinary API 198.8 127.4 56% Finished Finished Dosage Forms 20.0 13.4 49% Dosage Forms, 8% Human API 19.5 5.0 287% Veterinary API, 78% Intermediates 16

  6. Slide 6: Coupled with growth across regions

    Coupled with growth across regions FY21 Revenue Distribution Revenue (Rs Cr) FY21 FY20 YoY % ROW, 11% USA, 3% India, 22% Asia Pacific 82.1 43.1 90.6% Europe 80.7 49.7 62.4% India 57.3 38.3 49.4% Asia Pacific, 32% ROW 28.2 17.7 59.5% Europe, 32% USA 6.8 0.2 2919.9% 6

  7. Slide 7: Improving efficiencies

    Improving efficiencies Consolidated Figures ROCE (%) Debt/ Equity (x) Fixed Asset Turnover (x) 0.37 53% 3.4 0.29 0.29 2.5 2.3 2.0 27% 22% 0.11 12% FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 ROCE = EBIT / Avg Capital Employed (Shareholder’s Fund + Total Debt) Debt/Equity = Total Debt

  8. Slide 8: Consolidated profit & loss statement

    Consolidated profit & loss statement (Rs Cr) Q4FY21 Q4FY20 YoY FY21 FY20 YoY Revenue from operations 71.8 35.4 103% 258.0 151.7 70% Cost of material consumed 26.6 14.2 102.4 64.4 Gross Profit 45.2 21.2 113% 155.6 87.3 78% Gross Profit margin 63.0% 59.9% 60.3% 57.5% Employee expenses 7.4 5.9 28.1 24.

  9. Slide 9: Consolidated balance sheet highlights

    Consolidated balance sheet highlights Abridged Balance Sheet (Rs Cr) Mar-21 Mar-20 Shareholders' Funds 154 99 ▪ Net cash flow from operations of Rs Total Borrowings 16 28 27 crores was utilized in repaying Trade Payables 30 21 debt of Rs 12 crores during the year and for capex of Rs 17 crores Other

  10. Slide 10: Company Overview

    Company Overview

  11. Slide 11: Animal heath company with strong global footprint

    Animal heath company with strong global footprint Comprehensive product ▪ 22 APIs (18 veterinary API, 4 human), 4 intermediates, 10 finished dosage forms portfolio ▪ Best quality and value-driven pricing Market leadership in vet ▪ Leadership in top 3 products – 50%+ market share API ▪ Growing positi

  12. Slide 12: Leadership in veterinary API on the back of superior quality

    Leadership in veterinary API on the back of superior quality Wide Range of Product Categories Strong controls of processes with 95% in-house High quality and reliable Anthelmintics manufacturing and backward products with no market Ectoparasiticides integrated facilities leading rejection in 15 year

  13. Slide 13: State-of-the-art manufacturing capabilities

    State-of-the-art manufacturing capabilities 3 manufacturing facilities located at Tarapur & Navi Mumbai, Maharashtra, designed to meet the requirements of regulatory agencies and are capable of a wide range of reaction capabilities 10,000 m2 102 m3 194 m3 Area of manufacturing Glass-lined reactors S

  14. Slide 14: Promoters

    Represented by a professional team & Board Mr. Rahul Nachane Mr. Rajesh Lawande Whole-Time Director & CFO Promoters Managing Director • 30+ years of experience in the pharmaceutical industry • 20+ years of experience in the pharmaceutical industry • Is involved in the operations of the Company since

  15. Slide 15: Advantageously placed in a growing opportunity

    Advantageously placed in a growing opportunity Market Size 2020 Market Size 2027 Segment Trends Growth Drivers ▪ Pharma segment to grow ▪ Rising prevalence of at higher rate – 5.4% Animal Health zoonotic diseases, animal $192 Billion CAGR Market $139 Billion (CAGR – 4.7%) population & pet ownership

  16. Slide 16: On strategic growth path

    On strategic growth path Next leg of exponential growth Continous investments to tap 2024 Onwards opportunities New capex yet to be 2022-23 1. Greenfield capacity expansion leveraged planned at Tarapur 2019 to 2021 1. Complete Rs 20 crores expansion in Macrotech during FY22, will ▪ Capacity expansio

  17. Slide 17: Historical Financials

    Historical Financials

  18. Slide 18: Robust financial performance

    Robust financial performance Consolidated Figures Revenue (Rs Cr) EBITDA (Rs Cr) PAT (Rs Cr) 31% CAGR 55% CAGR 65% CAGR 258 79.7 57 153 152 116 32.1 20 21.3 19.4 13 8 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 Gross Margin (%) EBITDA Margin (%) PAT Margin (%) 31% 22% 60% 59% 60% 58%

  19. Slide 19: Thank You

    Thank You NGL Fine-Chem Ltd Pareto Capital (Investor Relations) Pallavi Pednekar (Company Pooja Dokania Secretary) pooja.dokania@paretocapital.in cs@nglfinechem.com Rishav Das rishav.das@paretocapital.in 19

NGL Fine-Chem — Q4 FY2021 Earnings Presentation on 6ix